期刊文献+

成人重组酵母乙肝疫苗两种不同免疫程序接种效果观察 被引量:13

Effects of two immunization schedules of recombinant yeast-derived hepatitis B vaccine for adults
原文传递
导出
摘要 目的探讨成人乙肝疫苗两种不同免疫程序接种效果。方法对381名16~49岁年龄组HBsAg、抗-HBs、抗-HBc指标均为阴性者,采用0、1、3个月和0、1、6个月免疫程序接种10μg重组酵母乙肝疫苗,进行免疫效果观察。阳转率的比较采用χ2检验,抗-HBs GMT比较采用t检验,趋势检验采用相关分析,P<0.05差异有统计学意义。结果应用国产10μg重组酵母乙肝疫苗,采取0、1、3个月和0、1、6个月免疫程序后1个月抗-HBs阳性率分别为88.95%和90.05%,差异无统计学意义(χ2=0.124,P>0.05);几何平均滴度(GMT)分别为94.95IU/L和145.12IU/L,差异有统计学意义(t=-2.007,P=0.045);随着年龄增加,其免后抗–HBsGMT呈下降趋势(r=-0.117,P=0.023)。结论采取0、1、3个月和0、1、6个月免疫程序接种10μg重组酵母乙肝疫苗均可获得良好的抗体阳转率,后者产生的抗体滴度水平更高;且成人接种免疫年龄越小效果越好。 Objective To evaluate the effects of recombinant yeast-derived hepatitis B vaccine for adults vaccinated based on two immunization schedules.Methods A total of 381 adults aged 16-49 years with negative HBsAg,anti-HBs,and anti-HBc were randomly enrolled in the study.190 were inoculated 10 μg recombinant yeast-derived hepatitis B vaccine at months of 0,1 and 3,while others were vaccinated at months of 0,1 and 6.Anti-HBs level was measured one month after the final dose.Chi square test and t test were used to analyze the data.Results The positive rates of anti-HBs were 88.95% and 90.05% respectively,showing no significant difference between the two immunization schedules(χ2=0.124,P0.05).However,the difference of geometric mean titer(GMT)was statistically significant(94.95mIU/ml vs 145.12 IU/L,t=-2.00,P0.05).The GMT of anti-HBs showed a down-ward trend with age(r=-0.117,P=0.023).Conclusions The anti-HBs seroconversion rates are both high among adults inoculated with recombinant yeast-derived hepatitis B vaccine with two schedules,especially among those immunized at months 0,1 and 6.The younger the adult is,the better the effect will be.
出处 《中国预防医学杂志》 CAS 2013年第2期96-98,共3页 Chinese Preventive Medicine
基金 国家"十一五"科学技术重大专项(2009ZX10004-901)
关键词 重组酵母乙型肝炎疫苗 免疫程序 免疫效果 成人 Recombinant yeast-derived hepatitis B vaccine Immunization schedule Effect Adults
  • 相关文献

参考文献9

二级参考文献29

  • 1于万龙,徐桂珍,巴桂霞,王庭志,袁俭道,蔡唯一,承吉,徐国强,穆振宇.乙型肝炎血源疫苗的免疫持久性及加强免疫后的抗体应答[J].中国生物制品学杂志,1991,4(4):181-184. 被引量:1
  • 2Keating GM, Noble S. Recombinant hepatitis B vaccine (Engerix - B: a review of its immunogenicity and protective efficacy against hepatitis B). Drugs, 2003, 60 (10): 1021-1051.
  • 3Idilman R, De MN, Colantoni A, et al. The effect of high dose and short interval HBV vaccination in individuals with chronic hepatitis B. Am J Gastroenterol, 2002, 97 (3) : 435 -439.
  • 4Rendi -Wagner P, Kundi M, Stemberger H, et al. Antibody -response to three recombinant hepatitis B vaccines: cinoaratuve evaluation of multicenter travel - clinic based experience. Vaccine, 2001, 19 (1): 2055-2060.
  • 5龚晓红,王富珍,吴疆,刘立荣,韩莉莉,张弘,徐志鑫,甘亚弟,刘利英,苏彦平,张海艳.不同种类国产基因重组乙型肝炎疫苗免疫原性观察[J].中国计划免疫,2007,13(4):316-318. 被引量:27
  • 6Mahoney FJ. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev 1999;12:351-366.
  • 7Van Damme P, Kane M, Meheus A. Integration of hepatitis B vaccination into national immunization programmes. BMJ 1997; 314:1033.
  • 8Hong Z, Zou S, Giulivi A. Hepatitis B and its control in Southeast Asia and China. Canada communicable disease report,2001; 27S3,Available from: URL:htpp://www.hc=sc.gc.ca/pphb=dgspsp/publicat / ccdr=rmtc/01vo127/27s3.27s3k e.html.
  • 9Maynard JE, Kane MA, Alter MJ, Hadler SC. Control of Hepatitis B by Immunisation: Global perspectives Viral Hepatitis and Liver Disease. New York: Alan R. Liss, Inc., 1986:967-969.
  • 10Francis DP. The public's health unprotected. Reversing a decade of underutflization of hepatitis B vaccine. JAMA 1995;274:1242-1243.

共引文献45

同被引文献157

引证文献13

二级引证文献79

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部